Dr Raman Narang - Oncologist

09/09/2026

One word can completely change how a scan result is understood: "Stable."

Many people assume that if cancer hasn't disappeared, the treatment isn't working.

But that's not always true.

For many advanced cancers, the goal of treatment is to stop the disease from growing or spreading. When scans show the cancer is stable, it often means the treatment is successfully controlling the disease—and that can be a very positive outcome.

Every scan result needs to be interpreted in the context of your diagnosis, treatment plan, symptoms, and overall health.

That's why it's so important not to judge a report by a single word.

Understanding what your oncologist means can replace fear with clarity.

💬 Was the term "stable disease" different from what you thought it meant? Let me know in the comments, and tell me what oncology term you'd like explained next.

📍Dr. Raman Narang

Medical Oncologist | Precision Oncology

Lajpat Nagar, New Delhi



(stable disease meaning, cancer scan results, medical oncologist, advanced cancer treatment, precision oncology, cancer treatment response, oncology consultation, cancer education, South Delhi oncologist, Lajpat Nagar oncologist, cancer specialist Delhi, PET scan interpretation)

07/09/2026

Doctor, I have Stage IV lymphoma. Does this mean I cannot be cured?”

This is one of the first fears many patients have after hearing the words “Stage IV.”

And it is completely understandable.

But lymphoma is different from many solid cancers in the way staging works.

Stage IV lymphoma does not automatically mean that the disease is incurable.

The stage tells us about where the lymphoma is present. But the treatment plan and prognosis depend on much more — including the exact type of lymphoma, its biology, whether it is aggressive or indolent, the patient's overall health, and most importantly, how the disease responds to treatment.

Some advanced-stage lymphomas are treated with curative intent. Hodgkin lymphoma, for example, can still be curable even when diagnosed at an advanced stage.

So if you or someone you love has just been told “Stage IV lymphoma,” don't let those two words become the entire diagnosis.

Ask what type of lymphoma it is.

Ask what the goal of treatment is.

And ask your oncologist what the stage means specifically for you.

Every cancer diagnosis needs context. A number alone cannot tell the whole story.



[blood cancer awareness, lymphoma, stage 4 lymphoma, lymphoma treatment, lymphoma cure, Hodgkin lymphoma, non Hodgkin lymphoma, cancer awareness, oncology, medical oncologist]

03/09/2026

Cancer doesn’t check your age, bank balance, lifestyle or social status before it happens.
And that is exactly why we need to stop thinking of cancer as something that “happens to other people.”

You can do many things right and still develop cancer. What matters is awareness, recognising concerning changes, appropriate screening, and seeking medical advice when something doesn’t feel right.

Don’t live in fear. Live informed.

Save this reel. Share it with someone who needs the reminder.



[ cancer awareness, cancer symptoms, cancer screening, cancer prevention, oncology, cancer facts, early detection, cancer risk, medical oncologist, cancer care, health awareness, Dr Raman Narang, south delhi, delhi, oncologist, chemotherapy, immunotherapy, target therapy, lajpatnagar, doctor, cancer, cancer specialist, lajpatnagar cancer specialist, cancer doctor]

03/09/2026

Cancer doesn’t check your age, bank balance, lifestyle or social status before it happens.

And that is exactly why we need to stop thinking of cancer as something that “happens to other people.”

You can do many things right and still develop cancer. What matters is awareness, recognising concerning changes, appropriate screening, and seeking medical advice when something doesn’t feel right.

Don’t live in fear. Live informed.

Save this reel. Share it with someone who needs the reminder.



[ cancer awareness, cancer symptoms, cancer screening, cancer prevention, oncology, cancer facts, early detection, cancer risk, medical oncologist, cancer care, health awareness, Dr Raman Narang, south delhi, delhi, oncologist, chemotherapy, immunotherapy, target therapy, lajpatnagar, doctor, cancer, cancer specialist, lajpatnagar cancer specialist, cancer doctor]

31/08/2026

In oncology, the goal isn't to give more treatment. The goal is to give the right treatment.
There are times when another chemotherapy cycle, another scan, or another medication is exactly what's needed. And there are times when the wiser decision is to pause, change direction, or avoid treatments that may add more burden than benefit.

These decisions are never about doing less—they're about doing what is most likely to help the individual patient based on evidence, clinical judgment, and treatment goals.
Sometimes the most experienced decision isn't asking, "What else can we do?"

It's asking, "What will truly help this patient?"

💬 Have you ever been surprised to learn that in medicine, doing less can sometimes be the better decision? Share your thoughts below.

📍Dr. Raman Narang
Medical Oncologist | Precision Oncology
Lajpat Nagar, New Delhi



(medical oncologist, cancer treatment decisions, chemotherapy, PET scan, personalized cancer care, evidence based medicine, clinical judgment, oncology consultation, precision oncology, South Delhi oncologist, Lajpat Nagar oncologist, cancer specialist Delhi)

27/08/2026

What if the next big step in cancer treatment isn't simply a new drug — but a treatment designed around the individual tumour?

New Phase III results in melanoma are giving that idea serious attention.

A personalized mRNA therapy called intismeran autogene, used with pembrolizumab, met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in 1,137 patients with completely resected high-risk melanoma.

But there is an important caveat: the detailed Phase III efficacy numbers have not yet been released. So this is promising research — not a universal “cancer vaccine,” and not yet a reason to assume every cancer patient will benefit.

Earlier 5-year Phase IIb data are encouraging, showing a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death when the personalized therapy was combined with pembrolizumab.

For an oncologist, perhaps the most interesting part is the bigger direction of travel:

Cancer treatment is becoming increasingly personal.

Save this post — because this is a story worth following as the complete Phase III data emerge.

Dr. Raman Narang | Medical Oncologist | Precision Oncology



[personalized cancer vaccine, mRNA cancer vaccine, melanoma treatment, cancer research 2026, precision oncology, personalized cancer treatment, neoantigen therapy, mRNA therapy, cancer immunotherapy, melanoma vaccine, oncology research, cancer treatment breakthrough]

26/08/2026

Could we really make a cancer vaccine specifically for one patient? In the Phase 3 trial, adding this personalised therapy to pembrolizumab produced a statistically significant and clinically meaningful improvement in recurrence-free survival and distant metastasis-free survival compared with pembrolizumab alone. we should resist headlines suggesting that we now have a universally available “cancer vaccine.”

There are still important questions:

• How large is the absolute benefit?
• Will an overall-survival advantage emerge?
• Which patients benefit most?
• How quickly and economically can an individual vaccine be manufactured?
• Can the approach work as well in cancers with fewer mutations?

26/08/2026

Could we really make a cancer vaccine specifically for one patient? In the Phase 3 trial, adding this personalised therapy to pembrolizumab produced a statistically significant and clinically meaningful improvement in recurrence-free survival and distant metastasis-free survival compared with pembrolizumab alone. we should resist headlines suggesting that we now have a universally available “cancer vaccine.”

There are still important questions:

• How large is the absolute benefit?
• Will an overall-survival advantage emerge?
• Which patients benefit most?
• How quickly and economically can an individual vaccine be manufactured?
• Can the approach work as well in cancers with fewer mutations?

There is, however, encouraging longer-term evidence behind the concept.

24/08/2026